innovation HEALTH®
AETNA | INOVA

2018 Tracleer® (bosentan) Prior Authorization Request

Page 1 of 2
(You must complete both pages.)

Fax completed form to: 1-800-639-9158 **For urgent requests, please call: 1-800-551-2694**

Patient information		**Prescriber information**	
Patient name		Today's date	Physician specialty
Patient insurance ID number		Physician name	NPI/DEA number
Patient address, city, state, ZIP		Physician address, city, state, ZIP	
Patient home telephone number		M.D. office telephone number	
Gender ☐ Male ☐ Female	Patient date of birth	M.D. office fax number	

Diagnosis and medical information

Medication requested ☐ Tracleer (bosentan) tablets: ☐ 62.5mg ☐ 125mg		**Frequency**	
New prescription OR date therapy initiated	**Quantity**	**Day supply**	**Expected length of therapy**

Diagnosis (*Please check all boxes that apply and include all office notes supporting diagnosis.)*

☐ World Health Organization (WHO) Group I pulmonary arterial hypertension
☐ Other diagnosis/(ICD 10): _____

Please check all boxes that apply:

1. ☐ **All covered Part D drugs on any tier of the plan's formulary would not be as effective for the enrollee as the requested formulary drug and/or would likely have adverse effects for the enrollee.**

2. **For the diagnosis of WHO Group I pulmonary hypertension. Please complete this section.**

☐ Yes ☐ No Has the diagnosis been confirmed by right heart catheterization?
☐ Yes ☐ No Does the patient have a pretreatment mean pulmonary arterial pressure of greater than or equal to 25 mmHg?
☐ Yes ☐ No Does the patient have a pretreatment pulmonary capillary wedge pressure of less than or equal to 15 mmHg?
☐ Yes ☐ No Does the patient have a pretreatment pulmonary vascular resistance of greater than 3 Wood units?

Please complete this section below only if your patient does not meet the standard requirements listed above.
Please explain why your patient should be considered for exception although not meeting the plan's suggested PA criteria. Statement should include specifically which requirement is not met and why patient should be exempt from meeting this requirement. (Please note any information that is incomplete or illegible will delay the review process.)

_____
_____
_____
_____

(continued on page 2)

innovation HEALTH®
AETNA | INOVA

Please check all boxes that apply *(continued)*:

3. ☐ Yes ☐ No **Tracleer 62.5mg has a quantity limit (QL) of 120 tablets per 30 days and Tracleer 125mg has a quantity limit (QL) of 60 tablets per 30 days. Does the patient require higher dosage (quantity limit exception)?**

   ►If yes, indicate quantity requested: _____ per 30 days OR quantity _____ per day

   ☐ The number of doses available under the dose restriction for the prescription drug has been ineffective in the treatment of the enrollee's disease or medical condition.

   ☐ The number of doses available under the dose restriction for the prescription drug, based on both sound clinical evidence and medical and scientific evidence, the known relevant physical or mental characteristics of the enrollee, and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug's effectiveness or patient compliance.

4. ☐ **Please list all medications the patient has tried specific to the diagnosis and specify below.**

CURRENT/PAST MEDICATIONS USED	DATES OF TREATMENT	THERAPEUTIC OUTCOME

5. ☐ **Other supporting information**

*NOTE: All exception requests require prescriber supporting statements. Additionally, requests that are subject to prior authorization (or any other utilization management requirement), may require supporting information. Please attach supporting information, as necessary, for your request.

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. §§ 3729-3733. By signing this form, I represent that I have obtained patient consent as required under applicable state and federal law, including but not limited to the Health Information Portability and Accountability Act (HIPAA) and state re-disclosure laws related to HIV/AIDS.

Prescriber signature	**Date**